ComPro Pharma SRL
The score of ComPro Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -93 % Total assets -53 %
Accounts of the company itself (not consolidated).
The full file covers 6 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
ComPro Pharma's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 28 May 2026
- Year ended 31 Dec 2024filed on 20 Jun 2025
- Year ended 31 Dec 2023filed on 26 Jul 2024
- Year ended 31 Dec 2022filed on 12 Jun 2023
- Year ended 31 Dec 2021filed on 28 Jul 2022
ComPro Pharma's financial analysis
- Solvency11.9%sector median: 58.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of ComPro Pharma
ComPro Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0746.429.351
- VAT number
- BE0746429351
- Peppol
- Registered · 0208:0746429351 · as of 02 Nov 2026
- Legal form
- SRL
- Incorporated
- 21 Apr 2020
- Registered office
- 4140 Sprimont
- Latest accounts
- 2025 · filed on 28 May 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
ComPro Pharma (SRL) has been based in Sprimont since 2020, active in: research and experimental development on biotechnology. For 2025, it reports a net profit of 54,298 € and equity of 9,170 €; its revenue is not published. Its solvency stands at 11.9%, below the median of its sector (58.2%).
Companies similar to ComPro Pharma
Companies in the same business, of comparable size and area, outside its group.
- 1991 Southern Sky Research and experimental development on natural sciences and engineering Anderlecht · balance sheet 77,620 €
- NuStats Lab Research and experimental development on natural sciences and engineering Erpe-Mere · balance sheet 118,033 €
- Targeted Intelligence Strategic Orientation Research and experimental development on natural sciences and engineering Uccle · balance sheet 32,774 €
- Perpetuum CropScience Research and experimental development on natural sciences and engineering Beveren-Kruibeke-Zwijndrecht · balance sheet 181,346 €
- Greenewable Consulting & Management Research and experimental development on natural sciences and engineering Seraing · balance sheet 61,907 €
- ProteoFormiX Research and experimental development on natural sciences and engineering Vorselaar · balance sheet 182,817 €
- FoxBioPath Research and experimental development on natural sciences and engineering Duffel · balance sheet 103,842 €
- Biograbbit Research and experimental development on natural sciences and engineering Dendermonde · balance sheet 61,503 €
Frequently asked questions about ComPro Pharma
What is the revenue of ComPro Pharma?
ComPro Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of ComPro Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0746429351 for ComPro Pharma, if the company is VAT-registered. Its company number (CBE) is 0746.429.351.
Where is the registered office of ComPro Pharma?
According to the CBE register, the registered office of ComPro Pharma is in 4140 Sprimont.
What is the equity of ComPro Pharma?
At the close of the 2025 financial year, the equity of ComPro Pharma amounts to 9,170 €, a solvency of 11.9% of total assets.
Who manages ComPro Pharma?
The register lists 1 active mandates at ComPro Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of ComPro Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →